GlassScriptPhysician profile
Ginger Spiller
NPI 1053998518
$2,132.82
in general payments reported to CMS, 2019-2025
27 companies · $169 in 2025
The $169 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $146 · 2022: $1,009 · 2023: $810 · 2025: $169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $979.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $978.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $402.44 | 2022-2023 | |
| Glaxosmithkline, LLC. | $282.47 | 2022-2023 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $192.94 | 2022-2023 | Farxiga, Evusheld |
| Otsuka America Pharmaceutical, INC. | $184.43 | 2022-2023 | Rexulti |
| Enterra Medical, INC. | $168.75 | 2025 | |
| Novo Nordisk INC | $99.64 | 2021-2023 | Ozempic, Rybelsus |
| Pfizer INC. | $95.25 | 2021-2023 | |
| Idorsia Pharmaceuticals US INC | $80.86 | 2023 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.94 | 2022 | |
| Novartis Pharmaceuticals Corporation | $61.84 | 2022 | |
| Janssen Pharmaceuticals, INC | $55.38 | 2021-2022 | |
| Nevro Corp. | $46.32 | 2022 | |
| Lilly USA, LLC | $41.64 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $40.36 | 2022 | |
| Corium, LLC | $40.05 | 2023 | Azstarys |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $37.93 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.68 | 2021 | |
| Alfasigma USA, INC. | $34.56 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.55 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $21.90 | 2023 | |
| Xeris Pharmaceuticals, INC. | $19.90 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.43 | 2023 | |
| Esperion Therapeutics, INC. | $18.00 | 2021 | |
| Amneal Pharmaceuticals LLC | $17.64 | 2023 | Rytary |
| Astellas Pharma US INC | $17.02 | 2023 | Myrbetriq |
| Kowa Pharmaceuticals America, INC. | $13.45 | 2022 | |
| Dexcom, INC. | $11.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ginger Spiller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.